- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.06. | 'Not a horse and pony show': At FDA cell and gene roundtable, officials look for ways to cut red tape | ||
| 05.06. | Seyltx reserves option to boost chronic cough pipeline with 8 GluN2B antagonists | ||
| 05.06. | Chasing Sarepta, RegenXBio links DMD gene therapy to improved outcomes | ||
| 05.06. | Corcept unveils promising survival data from failed phase 2 ALS trial | ||
| 05.06. | Cullinan pens $700M pact for BCMA bispecific to pair with another autoimmune T cell engager | ||
| 04.06. | Rapt Therapeutics cuts staff for 2nd time in less than a year, continuing fallout from FDA hold | ||
| 04.06. | With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer field | ||
| 04.06. | Vigil's rare brain disease drug flunks phase 2 study, but Sanofi takeover is unaffected | ||
| 04.06. | Bayer's Vividion secures rights to world's only clinical-stage WRN inhibitor from partner Roche | ||
| 04.06. | Ascletis scores phase 3 win for daily acne pill, prepares push to Chinese regulators | ||
| 03.06. | Eli Lilly enlists Camurus to help unlock long-acting obesity market in deal worth up to $870M | ||
| 03.06. | Plexium cuts staff, realigns resources to support protein degrader pipeline | ||
| 03.06. | BioAge inks option agreement for Chinese biotech's obesity asset on heels of earlier APJ agonist setback | ||
| 03.06. | FDA, facing 4% budget cut, launches generative AI tool Elsa a month ahead of schedule | ||
| 03.06. | Transpire follows in Boehringer's footsteps by licensing PDE4 inhibitor for lung disease | ||
| 03.06. | Merck made $3B-plus offer for MoonLake-and could revive interest in late-phase biotech: FT | ||
| 03.06. | ASCO: OSE shares 65% overall survival rate behind therapeutic cancer vaccine's phase 2 win | ||
| 02.06. | 'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race | ||
| 02.06. | Precision medicine's next frontier: unlocking the power of biospecimens | ||
| 02.06. | ASCO's bubble of hope: Execs focus on 'rewriting textbooks' in cancer care at conference | ||
| 02.06. | Sanofi pays $15M for another STAT6 degrader from fruitful Nurix collab | ||
| 02.06. | Bristol Myers inks $11B BioNTech deal to join bispecific gold rush, leaping ahead of Merck and Pfizer | ||
| 02.06. | Regeneron pens $2B pact for Hansoh's potential obesity rival to Lilly's Zepbound | ||
| 02.06. | ASCO: Actuate's pancreatic cancer drug boosts survival by 3 months in phase 2 study | ||
| 02.06. | ASCO: AstraZeneca's oral SERD tied to 56% PFS benefit in phase 3 breast cancer trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .